| Schedule of Segment Profit or Loss, Including Significant Segment Expenses |
The table below provides a summary of the segment profit or loss, including significant segment expenses:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
March 31, |
|
|
|
2026 |
|
|
2025 |
|
Revenues: |
|
|
|
|
|
|
License revenue |
|
$ |
463 |
|
|
$ |
1,163 |
|
Research and development expenses: |
|
|
|
|
|
|
Claseprubart program-related expenses: |
|
|
|
|
|
|
Clinical operation activity costs |
|
|
14,156 |
|
|
|
11,739 |
|
CMC activity costs |
|
|
3,713 |
|
|
|
3,811 |
|
Preclinical study activity costs |
|
|
320 |
|
|
|
1,041 |
|
Total claseprubart program-related expenses |
|
|
18,189 |
|
|
|
16,591 |
|
Discovery expenses |
|
|
1,363 |
|
|
|
900 |
|
Personnel and related costs |
|
|
8,635 |
|
|
|
5,847 |
|
Stock-based compensation expense |
|
|
4,848 |
|
|
|
2,475 |
|
Other costs |
|
|
1,493 |
|
|
|
1,190 |
|
Total research and development expenses |
|
|
34,528 |
|
|
|
27,003 |
|
General and administrative expenses: |
|
|
|
|
|
|
Stock-based compensation expense |
|
|
5,754 |
|
|
|
2,840 |
|
Personnel and related costs |
|
|
4,061 |
|
|
|
2,561 |
|
Other costs |
|
|
2,653 |
|
|
|
1,936 |
|
Total general and administrative expenses |
|
|
12,468 |
|
|
|
7,337 |
|
Other income, net |
|
|
5,699 |
|
|
|
3,666 |
|
Net loss |
|
$ |
(40,834 |
) |
|
$ |
(29,511 |
) |
|